Targeting sodium channels in cardiac arrhythmia

Current Opinion in Pharmacology

Volumn 15, Issue 1, 2014, Pages 53-60

  Remme, Carol Ann ^a   Wilde, Arthur Am ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; FLECAINIDE; GS 458967; LIDOCAINE; MEXILETINE; QUINIDINE; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ARTICLE; BRUGADA SYNDROME; CALCIUM CHANNELOPATHY; CALCIUM HOMEOSTASIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENZYME REGULATION; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TOXICITY; LONG QT SYNDROME 3; LUNG FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SCN5A GENE; TORSADE DES POINTES;

ARRHYTHMIAS, CARDIAC; HUMANS; MOLECULAR TARGETED THERAPY; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; SODIUM CHANNEL BLOCKERS;

EID: 84890903987     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.11.014     Document Type: Review

References (54)

1. M.B. Rook, M.M. Evers, M.A. Vos, and M.F. Bierhuizen Biology of cardiac sodium channel Nav1.5 expression Cardiovasc Res 93 2012 12 23
2. C.A. Remme Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects J Physiol 591 2013 4099 4116
3. H. Abriel Cardiac sodium channel Na(v)1.5 and interacting proteins: physiology and pathophysiology J Mol Cell Cardiol 48 2010 2 11
4. A.A. Wilde, and R. Brugada Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel Circ Res 108 2011 884 897
5. C.A. Remme, and C.R. Bezzina Sodium channel (dys)function and cardiac arrhythmias Cardiovasc Ther 28 2010 287 294
6. P.J. Schwartz, S.G. Priori, C. Spazzolini, A.J. Moss, G.M. Vincent, C. Napolitano, I. Denjoy, P. Guicheney, G. Breithardt, M.T. Keating, J.A. Towbin, A.H. Beggs, P. Brink, A.A. Wilde, L. Toivonen, W. Zareba, J.L. Robinson, K.W. Timothy, V. Corfield, D. Wattanasirichaigoon, C. Corbett, W. Haverkamp, E. Schulze-Bahr, M.H. Lehmann, K. Schwartz, P. Coumel, and R. Bloise Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias Circulation 103 2001 89 95 (Pubitemid 32050441)
7. Y. Mizusawa, and A.A. Wilde Brugada syndrome Circ Arrhythm Electrophysiol 5 2012 606 616
8. C.A. Remme, A.A. Wilde, and C.R. Bezzina Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations Trends Cardiovasc Med 18 2008 78 87 (Pubitemid 351626603)
9. D.P. Zipes, and H.J. Wellens Sudden cardiac death Circulation 98 1998 2334 2351 (Pubitemid 28533855)
10. A.D. Perron, and T. Sweeney Arrhythmic complications of acute coronary syndromes Emerg Med Clin North Am 23 2005 1065 1082 (Pubitemid 41400100)
11. M.J. Janse, and A.L. Wit Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction Physiol Rev 69 1989 1049 1169 (Pubitemid 19255835)
12. M. Rubart, and D.P. Zipes Mechanisms of sudden cardiac death J Clin Invest 2005 115
13. S. Nattel, A. Maguy, S. Le Bouter, and Y.H. Yeh Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation Physiol Rev 87 2007 425 456 (Pubitemid 47084677)
14. J.D. Moreno, and C.E. Clancy Pathophysiology of the cardiac late Na current and its potential as a drug target J Mol Cell Cardiol 52 2012 608 619
15. + current - origin and pathophysiological relevance Cardiovasc Drugs Ther 27 2013 61 68
16. C.A. Remme, and A.A. Wilde Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias Cardiovasc Drugs Ther 27 2013 91 101
17. A. Zaza, L. Belardinelli, and J.C. Shryock Pathophysiology and pharmacology of the cardiac 'late sodium current' Pharmacol Ther 119 2008 326 339
18. A.A. Wilde Proarrhythmia related to sodium channel blockade: mechanisms, monitoring, prevention and management Card Electrophysiol Rev 2 1998 136 141 (Pubitemid 128510586)
19. D.S. Echt, P.R. Liebson, and L.B. Mitchell et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788
20. H.M. Greenberg, E.M. Dwyer Jr., J.S. Hochman, J.S. Steinberg, D.S. Echt, and R.W. Peters Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I Br Heart J 74 1995 631 635 (Pubitemid 26004633)
21. H.R. Lu, J. Rohrbacher, E. Vlaminckx, K. Van Ammel, G.X. Yan, and D.J. Gallacher Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers Br J Pharmacol 160 2010 60 76
22. + current of guinea-pig ventricular myocytes J Mol Cell Cardiol 28 1996 893 903 (Pubitemid 26169299)
23. H.S. Kim, H.N. Pak, J.S. Park, and S.S. Kim Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia Pacing Clin Electrophysiol 2010 1 3
24. L. Belardinelli, J.C. Shryock, and H. Fraser Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine Heart 92 Suppl. 4 2006 iv6 iv14
25. C. Antzelevitch, A. Burashnikov, S. Sicouri, and L. Belardinelli Electrophysiologic basis for the antiarrhythmic actions of ranolazine Heart Rhythm 8 2011 1281 1290
26. M.J. Koren, M.R. Crager, and M. Sweeney Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE) J Am Coll Cardiol 49 2007 1027 1034 (Pubitemid 46349506)
27. A.J. Moss, W. Zareba, K.Q. Schwarz, S. Rosero, S. McNitt, and J.L. Robinson Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome J Cardiovasc Electrophysiol 19 2008 1289 1293
28. + current J Cardiovasc Pharmacol 51 2008 581 589
29. L. Belardinelli, G. Liu, and C. Smith-Maxwell et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias J Pharmacol Exp Ther 344 2013 23 32
30. S. Sicouri, L. Belardinelli, and C. Antzelevitch Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967 Heart Rhythm 10 2013 1036 1043
31. H. Clements-Jewery, D.J. Hearse, and M.J. Curtis Phase 2 ventricular arrhythmias in acute myocardial infarction Br J Pharmacol 145 2005 551
32. D.G. Julian, A.J. Camm, and G. Frangin et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT Lancet 349 1997 667 674 (Pubitemid 27107744)
33. G.H. Bardy, K.L. Lee, and D.B. Mark et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237 (Pubitemid 40110811)
34. N.J. Wimmer, and P.H. Stone Anti-anginal and anti-ischemic effects of late sodium current inhibition Cardiovasc Drugs Ther 27 2013 69 77
35. T.J. Bunch, S. Mahapatra, and D. Murdock et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks Pacing Clin Electrophysiol 34 2011 1600 1606
36. B.M. Scirica, D.A. Morrow, and H. Hod et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652 (Pubitemid 47537839)
37. 2+ accumulation in chronic heart failure J Physiol Sci 60 2010 245 257
38. C. Jacobshagen, L. Belardinelli, G. Hasenfuss, and L.S. Maier Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study Clin Cardiol 34 2011 426 432
39. R. Spoladore, M.S. Maron, R. D'Amato, P.G. Camici, and I. Olivotto Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence Eur Heart J 33 2012 1724 1733
40. J.W. Kaliebe, and D.K. Murdock Suppression of non-sustained ventricular tachycardia with ranolazine: a case report Wis Med J 108 2009 373 375
41. 2+ overload and inhibited by ranolazine J Mol Cell Cardiol 47 2009 326 334
42. S.G. Priori, C. Napolitano, P.J. Schwartz, M. Grillo, R. Bloise, E. Ronchetti, C. Moncalvo, C. Tulipani, A. Veia, G. Bottelli, and J. Nastoli Association of long QT syndrome loci and cardiac events among patients treated with β-blockers JAMA 292 2004 1341 1344 (Pubitemid 39223225)
43. L. Wu, J.C. Shryock, Y. Song, Y. Li, C. Antzelevitch, and L. Belardinelli Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome J Pharmacol Exp Ther 310 2004 599 605 (Pubitemid 38992327)
44. D.P. Shah, J.L. Baez-Escudero, I.L. Weisberg, J.F. Beshai, and M.C. Burke Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8) Pacing Clin Electrophysiol 35 2012 e62 e64
45. C.A. Remme, A.O. Verkerk, W.M. Hoogaars, W.T. Aanhaanen, B.P. Scicluna, C. Annink, M.J. van den Hoff, A.A. Wilde, T.A. van Veen, M.W. Veldkamp, J.M. de Bakker, V.M. Christoffels, and C.R. Bezzina The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium Basic Res Cardiol 104 2009 511 522
46. A. Burashnikov, J.M. Di Diego, and A.C. Zygmunt et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 2007 1449 1457 (Pubitemid 47480635)
47. S. Petitprez, A.F. Zmoos, J. Ogrodnik, E. Balse, N. Raad, S. El-Haou, M. Albesa, P. Bittihn, S. Luther, S.E. Lehnart, S.N. Hatem, A. Coulombe, and H. Abriel SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes Circ Res 108 2011 294 304
48. V1.5 distribution in myocytes via interacting proteins: the multiple pool model Biochim Biophys Acta 1833 2013 886 894
49. X. Lin, N. Liu, J. Lu, J. Zhang, J.M. Anumonwo, L.L. Isom, G.I. Fishman, and M. Delmar Subcellular heterogeneity of sodium current properties in adult cardiac ventricular myocytes Heart Rhythm 8 2011 1923 1930
50. V. Haufe, C. Chamberland, and R. Dumaine The promiscuous nature of the cardiac sodium current J Mol Cell Cardiol 42 2007 469 477 (Pubitemid 46349127)
51. A.W. Herren, D.M. Bers, and E. Grandi Post-translational modifications of the cardiac Na channel: contribution of CaMKII-dependent phosphorylation to acquired arrhythmias Am J Physiol Heart Circ Physiol 305 2013 H431 H445
52. + influx activates CaMKII in rat ventricular myocytes and N1325S mice Am J Physiol Cell Physiol 301 2011 C577 C586
53. E.M. Lodder, B.P. Scicluna, A. Milano, A.Y. Sun, H. Tang, C.A. Remme, P.D. Moerland, M.W. Tanck, G.S. Pitt, D.A. Marchuk, and C.R. Bezzina Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction PLoS Genet 8 2012 e1003113
54. C.R. Bezzina, J. Barc, Y. Mizusawa, C.A. Remme, J.B. Gourraud, F. Simonet, A.O. Verkerk, P.J. Schwartz, L. Crotti, F. Dagradi, P. Guicheney, V. Fressart, A. Leenhardt, C. Antzelevitch, S. Bartkowiak, E. Schulze-Bahr, S. Zumhagen, E.R. Behr, R. Bastiaenen, J. Tfelt-Hansen, M.S. Olesen, S. Kääb, B.M. Beckmann, P. Weeke, H. Watanabe, N. Endo, T. Minamino, M. Horie, S. Ohno, K. Hasegawa, N. Makita, A. Nogami, W. Shimizu, T. Aiba, P. Froguel, B. Balkau, O. Lantieri, M. Torchio, C. Wiese, D. Weber, R. Wolswinkel, R. Coronel, B.J. Boukens, S. Bézieau, E. Charpentier, S. Chatel, A. Despres, F. Gros, F. Kyndt, S. Lecointe, P. Lindenbaum, V. Portero, J. Violleau, M. Gessler, H.L. Tan, D.M. Roden, V.M. Christoffels, H. Le Marec, A.A. Wilde, V. Probst, J.J. Schott, C. Dina, and R. Redon Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death Nat Genet 45 2013 1044 1049